The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The global pipeline of new medicines for the control and elimination of malaria
Open accessAbstract
Over the past decade, there has been a transformation in the portfolio of medicines to combat malaria. New fixed-dose artemisinin combination therapy is available, with four different types having received approval from Stringent Regulatory Authorities or the World Health Organization (WHO). However, there is still scope for improvement. The Malaria Eradication Research agenda identified several gaps in the current portfolio. Simpler regimens, such as a single-dose cure are needed, compared with the current three-day treatment. In addition, new medicines that prevent transmission and also relapse are needed, but with better safety profiles than current medicines. There is also a big opportunity for new medicines to prevent reinfection and to provide chemoprotection. This study reviews the global portfolio of new medicines in development against malaria, as of the summer of 2012. Cell-based phenotypic screening, and ‘fast followers’ of clinically validated classes, mean that there are now many new classes of molecules starting in clinical development, especially for the blood stages of malaria. There remain significant gaps for medicines blocking transmission, preventing relapse, and long-duration molecules for chemoprotection. The nascent pipeline of new medicines is significantly stronger than five years ago. However, there are still risks ahead in clinical development and sustainable funding of clinical studies is vital if this early promise is going to be delivered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Kaye, D. K., Nshemerirwe, R., Mutyaba, T. S., & Ndeezi, G. (2008) · Journal of Infection in Developing Countries · doi:10.3855/t2.2.135 · Cited by 27
Lacaze, C., Kauss, T., Kiechel, J.-R., Caminiti, A., Fawaz, F., Terrassin, L., Cuart, S., Grislain, L., Navaratnam, V., Ghezzoul, B., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-142 · Cited by 24
Cited by
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Self-citationDrug repurposing and human parasitic protozoan diseases
Andrews, K. T., Fisher, G., & Skinner-Adams, T. S. (2014) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.02.002 · Cited by 383
Phillips, M. A., Lotharius, J., Marsh, K., White, J., Dayan, A., White, K. L., Njoroge, J. W., El Mazouni, F., Lao, Y., Kokkonda, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa6645 · Cited by 371
Self-citationThe Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases
Spangenberg, T., Burrows, J. N., Kowalczyk, P., McDonald, S., Wells, T. N. C., & Willis, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062906 · Cited by 341
Self-citationGeographical variation in Plasmodium vivax relapse
Battle, K. E., Karhunen, M. S., Bhatt, S., Gething, P. W., Howes, R. E., Golding, N., Van Boeckel, T. P., Messina, J. P., Shanks, G. D., Smith, D. L., et al. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-144 · Cited by 282
Metadata
- Authors
- Anthony, M. P., Burrows, J. N., Duparc, S., JMoehrle, J., & Wells, T. N.
- Venue
- Malaria Journal
- Published
- 2012-09-07
- Volume
- 11
- Issue
- 1
- Pages
- 316-316
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2095957613
- Cited by
- 167
- References
- 3
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The global pipeline of new medicines for the control and elimination of malaria. https://app.cochat.ai/papers/10.1186/1475-2875-11-316
- The paper
- Anthony, M. P., Burrows, J. N., Duparc, S., JMoehrle, J., & Wells, T. N. (2012). The global pipeline of new medicines for the control and elimination of malaria. Malaria Journal. https://doi.org/10.1186/1475-2875-11-316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.